Figure 4
From: Fatigue-induced Orosomucoid 1 Acts on C-C Chemokine Receptor Type 5 to Enhance Muscle Endurance
CCR5 in skeletal muscle mediates the anti-fatigue effect of ORM1.
(a,b) Swimming time ((a) n = 7) and muscle glycogen content ((b) n = 4) were assessed 30 minutes after intravenous injection of ORM1 (200 mg/kg) or vehicle in the presence or absence of Maraviroc (200 mg/kg, via gastric gavage, for three days). (c) Representative records of electrically evoked contractions of soleus muscle isolated from C57/BL mice treated as mentioned in (a) (n = 6). (d,e) Swimming times (d) and muscle glycogen content (e) were determined 30 min after treatment with ORM1 (200 mg/kg) or vehicle (Ctr) in CCR5+/+ or CCR5−/− mice (n = 4–6 per group). Maraviroc: MVC. Data are expressed as the mean ± s.d. NS, not significant, *P < 0.05, **P < 0.01 by Dunnett’s test.
